Now predictors of outcome in idiopathic pulmonary arterial hypertension

被引:180
作者
Kawut, SM
Horn, EM
Berekashvili, KK
Garofano, RP
Goldsmith, RL
Widlitz, AC
Rosenzweig, EB
Kerstein, D
Barst, RJ
机构
[1] Columbia Univ, Dept Internal Med, New York, NY USA
[2] Columbia Univ, Dept Pediat, Coll Phys & Surg, New York, NY USA
[3] Columbia Univ, Dept Epidemiol, Joseph L Mailman Sch Publ Hlth, New York, NY USA
关键词
D O I
10.1016/j.amjcard.2004.09.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Idiopathic pulmonary arterial hypertension (PAH) is a rare disease with a poor prognosis. New therapies have improved the outcome of this condition; accordingly, the factors that determine outcome may have changed. We aimed to identify determinants of survival in a cohort of consecutive patients with PAH: which was idiopathic, familial, or associated with anorexigen use. We performed a retrospective cohort study of 84 consecutive patients with PAH who underwent initial evaluation at our center from January 1994 to June 2002. The primary outcome was death or lung transplantation. Survival at 1, 2, and 3 years was 87%, 75%, and 61%, respectively. Multivariate analysis showed that being of African-American or Asian descent was associated with an increased risk of death. Warfarin use was associated with a reduced risk of death. Higher serum albumin and cardiac index and acute vasoreactivity were independently associated with improved survival. These data suggest that the determinants of outcome have changed. Race is identified as a new risk factor, which may be attributable to biologic or socioeconomic differences. Cardiac function and acute reactivity of the pulmonary vascular bed remain strong independent predictors of outcome. (C) 2005 by Excerpta Medica Inc.
引用
收藏
页码:199 / 203
页数:5
相关论文
共 29 条
[1]   A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].
Barst, RJ ;
Rubin, LJ ;
Long, WA ;
McGoon, MD ;
Rich, S ;
Badesch, DB ;
Groves, BM ;
Tapson, VF ;
Bourge, RC ;
Brundage, BH ;
Koerner, SK ;
Langleben, D ;
Keller, CA ;
Murali, S ;
Uretsky, BF ;
Clayton, LM ;
Jobsis, MM ;
Blackburn, SD ;
Shortino, D ;
Crow, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301
[2]   ASSESSMENT OF CARDIAC-PERFORMANCE WITH QUANTITATIVE RADIONUCLIDE ANGIOCARDIOGRAPHY - RIGHT VENTRICULAR EJECTION FRACTION WITH REFERENCE TO FINDINGS IN CHRONIC OBSTRUCTIVE PULMONARY-DISEASE [J].
BERGER, HJ ;
MATTHAY, RA ;
LOKE, J ;
MARSHALL, RC ;
GOTTSCHALK, A ;
ZARET, BL .
AMERICAN JOURNAL OF CARDIOLOGY, 1978, 41 (05) :897-905
[3]   The prognostic role of the ECG in primary pulmonary hypertension [J].
Bossone, E ;
Paciocco, G ;
Iarussi, D ;
Agretto, A ;
Iacono, A ;
Gillespie, BW ;
Rubenfire, M .
CHEST, 2002, 121 (02) :513-518
[4]  
COHEN M, 1990, PULMONARY CIRCULATIO, P501
[5]  
Cooper R, 2000, CIRCULATION, V102, P3137
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]   SURVIVAL IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION - RESULTS FROM A NATIONAL PROSPECTIVE REGISTRY [J].
DALONZO, GE ;
BARST, RJ ;
AYRES, SM ;
BERGOFSKY, EH ;
BRUNDAGE, BH ;
DETRE, KM ;
FISHMAN, AP ;
GOLDRING, RM ;
GROVES, BM ;
KERNIS, JT ;
LEVY, PS ;
PIETRA, GG ;
REID, LM ;
REEVES, JT ;
RICH, S ;
VREIM, CE ;
WILLIAMS, GW ;
WU, M .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (05) :343-349
[8]   The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension [J].
Frank, H ;
Mlczoch, J ;
Huber, K ;
Schuster, E ;
Gurtner, HP ;
Kneussl, M .
CHEST, 1997, 112 (03) :714-721
[9]   PRIMARY PULMONARY-HYPERTENSION - NATURAL-HISTORY AND THE IMPORTANCE OF THROMBOSIS [J].
FUSTER, V ;
STEELE, PM ;
EDWARDS, WD ;
GERSH, BJ ;
MCGOON, MD ;
FRYE, RL .
CIRCULATION, 1984, 70 (04) :580-587
[10]   Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension [J].
Galiè, N ;
Seeger, W ;
Naeije, R ;
Simonneau, G ;
Rubin, LJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) :81S-88S